Sangamo BioSciences, Inc. Reports Second Quarter 2013 Financial Results

... to our preclinical programs partially offset by lower clinical trial and manufacturing expenses for our SB-728-T HIV/AIDS program. General and administrative expenses were , at the 16th Annual Meeting of the American Society of Gene and Cell Therapy ...

http://www.biospace.com/news_story.aspx?StoryID=303692&full=1

Sangamo Biosciences, Inc. (SGMO) CEO Discusses Q2 2013 Results - Earnings Call Transcript

... of our lead clinical program SB-728-T, an autologous T-cell therapy designed to provide a functional cure for HIV/AIDS. Using our Zinc Finger Nuclease or ZFN technology, we can specifically disrupt the gene in coding CCR5, a required co-receptor for ...

http://seekingalpha.com/article/1569952-sangamo-biosciences-inc-sgmo-ceo-discusses-q2-2013-results-earnings-call-transcript?source=feed

Sangamo BioSciences, Inc's Management Presents Bank of America...

Sangamo BioSciences, Inc Bank of America Merrill Lynch Health Care Conference Call May 16, 2013 1:00 PM ET We'll get started.

http://seekingalpha.com/article/1441981-sangamo-biosciences-inc-s-management-presents-bank-of-america-merrill-lynch-health-care-conferencecall-transcript?source=feed